Exploitation and Development of “Synthetic Lethality” Strategy for Cancer Therapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 363
Special Issue Editor
Special Issue Information
Dear Colleagues,
“Synthetic lethality” is defined as a genetic interaction between co-occurring alterations of two individual genes that results in cell death. Synthetic lethality has emerged as a promising approach for designing combination therapies or novel anti-cancer agents. PARP inhibitors (PARPi) are the first clinically used anti-cancer drugs designed to exploit synthetic lethality, and they have achieved huge success in managing BRCA1/2-mutant cancers. Although PARPi are the first-line maintenance therapy for BRCA1/2-mutant ovarian cancers, required or de novo resistance has hindered their clinical efficacy. Therefore, novel “synthetic lethality” partners and targets are needed to design novel anti-cancer therapies. In addition, effective combination strategies are urgently needed to overcome PARPi resistance. Therefore, this Special Issue will accept submissions including, but not limited to, novel anti-cancer therapeutics based on “Synthetic lethality”, novel mechanisms exploring anti-cancer therpies, novel combination strategies to overcome PARPi, and novel molecular target and action mechanisms of anti-cancer drugs.
Dr. Guo Chen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anti-cancer therpies
- PARP inhibitors
- synthetic lethality
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
